34 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
9 May 24
Report of Foreign Private Issuer
7:03am
and the IND approval by FDA will allow for the recruitment of patients in the US.
The Phase IIb trial is a multicenter, randomized, double-blind, placebo … , Can-Fite CEO. " As we are already enrolling patients for this study, we hope that in the next few months, we will complete recruitment. We
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
2 May 22
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
7:09am
trial for the treatment of liver cancer is now open for the recruitment of patients
PETACH TIKVA, Israel, May 2, 2022 -- Can-Fite BioPharma Ltd … and the European Medicines Agency (EMA) and is now open for the recruitment of approximately 450 patients diagnosed with hepatocellular carcinoma (HCC
6-K
EX-99.1
u3bs01ubi26
22 Apr 21
Report of Foreign Private Issuer
7:26am
424B4
zwcurwi
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
250x5kvhgtjorf 6f
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
7kp7axt
24 Jan 20
Registration statement (foreign)
4:40pm
6-K
EX-99.1
08hdu0bq v2gf2
23 Sep 19
Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference
7:14am
20-F/A
np0l0
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
t5yl579pc5 yan2
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
i1r6tyw 3v
12 Mar 19
Registration statement (foreign) (amended)
4:20pm
F-1
890nv
15 Feb 19
Registration statement (foreign)
4:32pm